Journal of Nuclear Cardiology

, Volume 26, Issue 2, pp 486–492 | Cite as

FDG PET-CT findings of extra-thoracic sarcoid are associated with cardiac sarcoid: A rationale for using FGD PET-CT for cardiac sarcoid evaluation

  • Darshan C. Patel
  • Senthil S. Gunasekaran
  • Christopher Goettl
  • Nadera J. Sweiss
  • Yang LuEmail author
Original Article



This retrospective study investigates the relationship between cardiac and extra-thoracic sarcoid findings on FDG PET-CT using a 72-hour pretest high-fat, high-protein, and very low-carbohydrate (HFHPVLC) diet.

Patients and methods

A total of 196 consecutive FDG PET-CT scans with 72-hour HFHPVLC diet preparation were performed between December 2014 and December 2015 in known sarcoid patients. Of these scans, 5 were excluded for non-adherence to diet preparation or underlying cancer. Cardiac and extra-thoracic sarcoid lesions were categorized and measured for radiotracer uptake.


A total of 188 patients had 191 eligible FDG PET/CT scans (3 follow-up scans), of which there were 20 (10%) positive, 6 indeterminate (3%), and 165 (86%) negative for CS. Among the 20 scans positive for CS, 8 (40%) had findings of both cardiac and extra-thoracic sarcoid.


Our study shows that 40% of CS patients also have FDG PET-CT findings of extra-thoracic sarcoid. This makes an intriguing case for FDG PET-CT use with pretest diet prep over cardiac MRI (CMR) for cardiac sarcoid evaluation, given that CMR is likely to overlook these extra-thoracic sites of disease.


Cardiac Extra-thoracic Sarcoid Sarcoidosis FDG PET-CT 



High-fat, high-protein, and very low-carbohydrate


Cardiac sarcoid


Cardiac MRI


Institutional review board



All the authors, Darshan C. Patel, Senthil S. Gunasekaran, Christopher Goettl, Nadera J. Sweiss, and Yang Lu, state that they have nothing to disclose.

Supplementary material

12350_2017_962_MOESM1_ESM.pptx (212 kb)
Supplementary material 1 (PPTX 211 kb)


  1. 1.
    Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153-65.CrossRefGoogle Scholar
  2. 2.
    Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993;103:253-8.CrossRefGoogle Scholar
  3. 3.
    Albert CM, Chae CU, Grodstein F, Rose LM, Rexrode KM, Ruskin JN, et al. Prospective study of sudden cardiac death among women in the United States. Circulation 2003;107:2096-101.CrossRefGoogle Scholar
  4. 4.
    Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007;50:1914-31.CrossRefGoogle Scholar
  5. 5.
    Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: A Delphi study. Chest 2012;141:154-62.CrossRefGoogle Scholar
  6. 6.
    Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther 2016;6:50-63.Google Scholar
  7. 7.
    Mantini N, Williams B, Stewart J, Rubinsztain L, Kacharava A. Cardiac sarcoid: A clinician’s review on how to approach the patient with cardiac sarcoid. Clin Cardiol 2012;35:410-5.CrossRefGoogle Scholar
  8. 8.
    Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med 2014;55:99-106.CrossRefGoogle Scholar
  9. 9.
    Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. Am J Roentgenol 2008;190:W151-6.CrossRefGoogle Scholar
  10. 10.
    Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10.CrossRefGoogle Scholar
  11. 11.
    Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol 2011;18:926-36.CrossRefGoogle Scholar
  12. 12.
    Ishida Y, Yoshinaga K, Miyagawa M, Moroi M, Kondoh C, Kiso K, et al. Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med 2014;28:393-403.CrossRefGoogle Scholar
  13. 13.
    Morooka M, Moroi M, Uno K, Ito K, Wu J, Nakagawa T, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014;4:1.CrossRefGoogle Scholar
  14. 14.
    Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.Google Scholar
  15. 15.
    Soussan M, Brillet PY, Nunes H, Pop G, Ouvrier MJ, Naggara N, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:120-7.CrossRefGoogle Scholar
  16. 16.
    Lu Y, Grant C, Xie K, Sweiss NJ. Suppression of myocardial 18F-FDG uptake through prolonged high-fat, high-protein, and very-low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. Clin Nucl Med 2017;42:88-94.CrossRefGoogle Scholar
  17. 17.
    Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol 2016;23:1187-226.CrossRefGoogle Scholar
  18. 18.
    Ito K, Okazaki O, Morooka M, Kubota K, Minamimoto R, Hiroe M. Visual findings of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with cardiac sarcoidosis. Intern Med 2014;53:2041-9.CrossRefGoogle Scholar
  19. 19.
    Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.CrossRefGoogle Scholar
  20. 20.
    Lu Y, Sweiss NJ. MRI and FDG PET/CT imaging manifestations of cardiac sarcoidosis. Clin Nucl Med 2015;40:973-4.CrossRefGoogle Scholar
  21. 21.
    Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: With emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009;20:578-83.CrossRefGoogle Scholar
  22. 22.
    Rose AS, Tielker MA, Knox KS. Hepatic, ocular, and cutaneous sarcoidosis. Clin Chest Med 2008;29:509-24, ix.Google Scholar
  23. 23.
    Singh G, Sangolli P, Dash K, Grove S. Cutaneous sarcoidosis without systemic involvement. Indian J Dermatol Venereol Leprol 2000;66:43-4.Google Scholar
  24. 24.
    Okamoto H, Mizuno K, Ohtoshi E. Cutaneous sarcoidosis with cardiac involvement. Eur J Dermatol 1999;9:466-9.Google Scholar
  25. 25.
    Mana J, Marcoval J, Graells J, Salazar A, Peyri J, Pujol R. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol 1997;133:882-8.CrossRefGoogle Scholar
  26. 26.
    Marchell RM, Judson MA. Chronic cutaneous lesions of sarcoidosis. Clin Dermatol 2007;25:295-302.CrossRefGoogle Scholar
  27. 27.
    Warshauer DM, Lee JK. Imaging manifestations of abdominal sarcoidosis. Am J Roentgenol 2004;182:15-28.CrossRefGoogle Scholar
  28. 28.
    Judson MA. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med 2007;28:83-101.CrossRefGoogle Scholar
  29. 29.
    CerfPayrastre I, Liote F. Bone, joint, and muscle involvement in sarcoidosis. Sem Hop Paris 1997;73:945-52.Google Scholar
  30. 30.
    Holmes J, Lazarus A. Sarcoidosis: Extrathoracic manifestations. Dis Mon 2009;55:675-92.CrossRefGoogle Scholar
  31. 31.
    James DG, Sharma OP. Extrathoracic sarcoidosis. Proc R Soc Med 1967;60:992-4.Google Scholar
  32. 32.
    Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.CrossRefGoogle Scholar
  33. 33.
    Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-8.CrossRefGoogle Scholar
  34. 34.
    Ohira H, Tsujino I, Sato T, Yoshinaga K, Manabe O, Oyama N, et al. Early detection of cardiac sarcoid lesions with (18)F-fluoro-2-deoxyglucose positron emission tomography. Intern Med 2011;50:1207-9.CrossRefGoogle Scholar
  35. 35.
    Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683-90.CrossRefGoogle Scholar
  36. 36.
    Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Bergmann SR, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990;31:1749-56.Google Scholar

Copyright information

© American Society of Nuclear Cardiology 2017

Authors and Affiliations

  • Darshan C. Patel
    • 1
  • Senthil S. Gunasekaran
    • 1
  • Christopher Goettl
    • 1
  • Nadera J. Sweiss
    • 2
  • Yang Lu
    • 1
    • 3
    Email author
  1. 1.Department of Radiology, College of MedicineUniversity of IllinoisChicagoUSA
  2. 2.Department of Medicine, College of MedicineUniversity of IllinoisChicagoUSA
  3. 3.Department of Nuclear Medicine, Division of Diagnostic ImagingUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations